SCHEMBL5202212

SCHEMBL5202212

N#Cc1cccc(C(O)C[N+](=O)[O-])c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
FBP1 P09467 3/20 0.43
GRM4 Q14833 1/20 0.41
TNF P01375 1/20 0.40
GSK3B P49841 2/20 0.39
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KCNJ1 P48048 1/20 0.37
KCNH2 Q12809 1/20 0.37
ENPP2 Q13822 1/20 0.37
VCAM1 P19320 2/20 0.36
GLA P06280 1/20 0.36
GPR139 Q6DWJ6 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
MMP12 P39900 1/20 0.35
MMP13 P45452 1/20 0.35
S1PR1 P21453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6167267 0.90 FBP1 (0.48) ALDH1A1FBP1GRM4TNFCNR1
SCHEMBL28055450 0.81 ALDH1A1 (0.62) ALDH1A1FBP1GSK3BL3MBTL1KCNJ1
SCHEMBL28055451 0.81 ALDH1A1 (0.62) ALDH1A1FBP1GSK3BL3MBTL1KCNJ1
SCHEMBL3235781 0.78 ALDH1A1 (0.53) ALDH1A1FBP1MEN1HPGDKMT2A
SCHEMBL8949484 0.77 GSK3B (0.49) ALDH1A1FBP1GRM4TNFGSK3B
SCHEMBL6540746 0.77 S1PR1 (0.45) GRM4TNFGSK3BENPP2GLA
SCHEMBL6481575 0.77 S1PR1 (0.45) GRM4TNFGSK3BENPP2GLA
SCHEMBL4697927 0.77 S1PR1 (0.45) GRM4TNFGSK3BENPP2GLA
SCHEMBL23549441 0.76 ALDH1A1 (0.65) ALDH1A1GRM4MEN1HPGDKMT2A
SCHEMBL528891 0.76 ALDH1A1 (0.51) ALDH1A1FBP1MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458708-B1 HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-09-26 EP disclosed
US-7105548-B2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2006-09-12 US disclosed
EP-1458708-A4 HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-11-16 EP disclosed
US-20050020585-A1 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2005-01-27 US disclosed
EP-1458708-A2 HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003051315-A2 HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020585-A1 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN3A ALDH1A1 2269/4885FBP1 4579/4885GRM4 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.